louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01942252: COMPLICATIONS RELATED CARBOXYHEMOGLOBIN LEVELS IN SECOND HAND SMOKING PEDIATRIC TONSILLECTOMY PATIENTS
Official title: COMPLICATIONS OF SECOND HAND SMOKING IN PEDIATRIC TONSILLECTOMY PATIENTS
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Secondhand Smoking
Keywords: Secondhand smoking, pain, postoperative complications
Lead sponsor: Mustafa Kemal University
Sponsor class: OTHER
First posted: 2013-09-13
Enrollment: 100
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inclusion Criteria:

-Patients 1-12 years old scheduled for adenotonsillectomy; written informed consent.

Brief summary: The purpose of this study was to determine whether high carboxyhemoglobin level is a risk factor for postoperative adverse events in children exposured to carbon monoxide, especially enviromental tobacco smoke.

Detailed description: Also we want to measure bleeding volume and compare it with the carboxyhemoglobin levels.

Eligibility criteria: Inclusion Criteria:

-Patients 1-12 years old scheduled for adenotonsillectomy; written informed consent.

Exclusion Criteria:

* Active smokers, history of prematurity, bleeding disorders, hemolysis, severe pulmonary disease, home oxygen use, and inpatient hospitalisation≥24 h.

Primary outcomes:
measure: Correlatin between carboxyhemoglobib levels of the second hand smoking children and postoperative complications and pain
timeFrame: Postoperative 24 hours
Secondary outcomes:
measure: Correlation between carboxyhemoglobin levels of the second hand smoking children and intraoperative bleeding volume
timeFrame: Intraoperative period
Other outcomes:
measure: Correlation between carboxyhemoglobin levels and pain of the second hand smoking children
timeFrame: postoperative 24 hours
Locations:
city: Hatay
country: Turkey
facility: Mustafa Kemal University
Study officials:
affiliation: Mustafa Kemal University
name: ONUR KOYUNCU, ASSIST PROF
role: STUDY_DIRECTOR
References:
citation: Skolnick ET, Vomvolakis MA, Buck KA, Mannino SF, Sun LS. Exposure to environmental tobacco smoke and the risk of adverse respiratory events in children receiving general anesthesia. Anesthesiology. 1998 May;88(5):1144-53. doi: 10.1097/00000542-199805000-00003.
citation: Koop CE. Adverse anesthesia events in children exposed to environmental tobacco smoke: exposure to environmental tobacco smoke and the risk of adverse respiratory events in children receiving general anesthesia. Anesthesiology. 1998 May;88(5):1141-2. doi: 10.1097/00000542-199805000-00001. No abstract available.
Clinical trial NCT01206452: Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes
Official title: Use of Oral Steroids Before Circumferential Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation to Improve Outcomes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Atrial Fibrillation
Keywords: Atrial Fibrillation; Ablation
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2010-09-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to assess the efficacy of oral prednisone in improving the outcomes of pulmonary vein isolation with radiofrequency ablation.

Detailed description: The purpose of this study is:

1. To assess the efficacy of oral prednisone in improving the outcomes of pulmonary vein isolation with radiofrequency ablation.
2. To measure the inflammatory cytokine (TNF-α, IL-1, IL-6, IL-8) response to radiofrequency ablation for atrial fibrillation with or without prior prednisone treatment.

Eligibility criteria: Inclusion Criteria:

1. Able to provide written informed consent;
2. Scheduled for radiofrequency ablation procedure for treatment of atrial fibrillation

Exclusion Criteria:

1. History of heart failure (right or left or biventricular) or cardiomyopathy.
2. Immunosuppressive disorders and systemic fungal infection
3. Concurrent use of corticosteroids in one week prior recruitment.
4. Allergy or prednisone or its components.
5. Other medical conditions were use of corticosteroids is not recommended or contraindicated.
6. Patients with chronic and permanent atrial fibrillation.
7. Patients with established diagnosis of rheumatological and immunological disorders.

Primary outcomes:
measure: Number of Participants With Atrial Fibrillation Recurrence From 6 Months up to 12 Months
timeFrame: From 6 months up to 12 months post-procedure
Secondary outcomes:
measure: Number of Participants With Atrial Fibrillation Recurrence From 0 Months up to 3 Months
timeFrame: From 0 months up to 3 months post procedure
measure: Number of Participants With Atrial Fibrillation Recurrence From 3 Months up to 6 Months
timeFrame: From 3 months up to 6 months post-procedure
measure: Inflammatory Cytokine Response to Ablation Procedure
timeFrame: Immediately Post-Ablation Procedure
measure: Inflammatory Cytokine Response to Ablation Procedure
timeFrame: 24 Hours after Ablation Procedure
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University Of Kansas Medical Center
state: Kansas
Study officials:
affiliation: University of Kansas Medical Center
name: Dhanunjaya Lakkireddy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01730352: Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
Official title: Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Immune Thrombocytopenic Purpura
Helicobacter Pylori Infection
Keywords: immune thrombocytopenic purpura
chronic immune thrombocytopenic purpura
secondary immune thrombocytopenic purpura
Helicobacter pylori infection
Helicobacter pylori gastritis
children
adolescents
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2012-11-21
Enrollment: 100
Sex: ALL
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether eradication of Helicobacter pylori infection is effective in the improvement of platelet counts in children and adolescents with chronic ITP.

Detailed description: Helicobacter pylori infection has been associated with Immune Thrombocytopenic Purpura (ITP), and there is scientific evidence for the investigation and treatment of this bacterium for adult patients with ITP. However, in children this causal association is not clear, with few published studies.

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of chronic immune thrombocytopenic purpura
* children and adolescents up to 20 years

Exclusion Criteria:

* known hypersensitivity to any of the drugs
* recent treatment for H. pylori eradication

Primary outcomes:
measure: platelet response
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Irmandade da Santa Casa de Misericordia se Sao Paulo
city: Sao Paulo
country: Brazil
facility: Centro de Hematologia de Sao Paulo
city: Sao Paulo
country: Brazil
facility: Federal University of Sao Paulo
city: Sao Paulo
country: Brazil
facility: Hospital Estadual Infantil Darcy Vargas
Study officials:
affiliation: Federal University of São Paulo
name: Elisabete Kawakami, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03395652: Maternal Physical Activity and Pregnancy Outcome
Official title: Maternal Physical Activity and Pregnancy Outcome
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Pregnancy Complications
Keywords: pregnancy, physical activity, fetal growth
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
Collaborators: name: University of Belgrade
First posted: 2018-01-10
Enrollment: 0
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Mothers included in the study live in Belgrade, Serbia and are pregnant during 2018. They are asked to participate in the study at first ultrasound examination at week 12-14.

Brief summary: The aim of this study is to investigate the impact of maternal physical activity during pregnancy on pregnancy outcome. Primary, fetal growth during pregnancy abd birth weight will be examined.

Detailed description: During this study, the information on maternal physical activity will be collected and the impact on delivery and pregnancy complications as well as on neonatal complications will be evaluated. From the first visit at maternal care center, the information on socioeconomical and maternal characteristics will be collected. During pregnancy, fetal growth will be estimated by ultrasound. Physical activity will be measured using free app for measuring steps that mothers make during pregnancy. Using logistic regression, the impact of physical activity on pregnancy outcomes will be evaluated.

Eligibility criteria: Inclusion Criteria:

Healthy women with singleton pregnancies

-

Exclusion Criteria:

* Twins pregnancies. Mothers with preexisting conditions. Malformations.

Primary outcomes:
measure: Fetal growth
timeFrame: birth weight at birth
Secondary outcomes:
measure: Pregnancy complications
timeFrame: during pregnancy ( 9 months from start)
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03762252: Dry Needling of Scalene Muscle Trigger Points in Mechanical Neck Pain
Official title: Effects of Dry Needling of Active Trigger Points in the Scalene Muscles on Individuals With Mechanical Neck Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Lead sponsor: Universidad Rey Juan Carlos
Sponsor class: OTHER
First posted: 2018-12-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There is preliminary evidence suggesting that referred pain from active trigger points can play a relevant role in individuals with mechanical neck pain. Some studies have investigated the effectiveness of dry needling over the upper trapezius muscle in this population. However, other muscles, such as the scalene muscles, can be also relevant for neck pain symptoms. No study has investigated the effects of the application of dry needling over active trigger points in the scalenes muscles in a sample of patients with mechanical neck pain.


Eligibility criteria: Inclusion Criteria:

Generalized neck-shoulder pain with symptoms provoked by neck postures, neck movement, or palpation of the cervical musculature

Exclusion Criteria:

* whiplash injury;
* previous cervical or thoracic surgery;
* cervical radiculopathy or myelopathy;
* diagnosis of fibromyalgia syndrome;
* having undergone physical therapy in the previous 6 months;
* less than 18 or greater than 45 years of age
* fear to needles
* any respiratory disease, e.g., chronic brochitis

Primary outcomes:
measure: Changes in neck pain intensity with a numerical pain rate scale before and after the intervention
timeFrame: Baseline, one day (immediately post), 7 days (one week) and 30 days (one month) after the intervention
Secondary outcomes:
measure: Changes in oxigen saturation with a pulse oximeter before and after the intervention
timeFrame: Baseline, one day (immediately post), 7 days (one week) and 30 days (one month) after the intervention
measure: Changes in inspiratory vital capacity with an incentive spirometer before and after the intervention
timeFrame: Baseline, one day (immediately post), 7 days (one week) and 30 days (one month) after the intervention
measure: Changes in neck-related disability with the Neck Disability Index before and after the intervention
timeFrame: Baseline and 7 days (one week) and 30 days (one month) after the intervention
Other outcomes:
Locations:
city: Alcorcón
country: Spain
facility: César Fernández-de-las-Peñas
state: Madrid
Study officials:
affiliation: Universidad Rey Juan Carlos
name: César Fernández-de-las-Peñas
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00804752: Vitamin D Treatment in Patients With Chronic Hepatitis C
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Hepatitis C
Keywords: Patients with Chronic Hepatitis C
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2008-12-09
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: We hypothesize that patients with Ch.HCV have a low level of vitamin D, and that by raising their vitamin D levels by adding it to their standard treament of Pegylated Interferon and Ribavirin, there will be an increase in their sustained virological response.


Eligibility criteria: Inclusion Criteria:

* Chronic Hepatitis C Genotype 1

Exclusion Criteria:

* Vitamin D intoxication Renal Failure Liver Failure Malignancy

Primary outcomes:
measure: To increase the sustained virological response
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT01309152: Cefazolin Subcutaneous Microdialysis in Morbidly Obese Patients
Official title: Peri-and Postoperative Subcutaneous Adipose Tissue Cefazolin Determination Using Microdialysis in Morbidly Obese and Non-obese Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Morbid Obesity
Keywords: cefazolin
microdialysis
morbid obesity
pharmacokinetics
Lead sponsor: St. Antonius Hospital
Sponsor class: OTHER
First posted: 2011-03-07
Enrollment: 16
Sex: ALL
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 8 morbidly obese patients undergoing weight reducing surgery And 8 non-obese patients undergoing surgery which will require an arterial line, nadroparin and cefazolin administration perioperatively and postoperative stay at the Post-Anesthesia Care Unit.

Brief summary: The investigators hypothesize that cefazolin perfusion to subcutaneous adipose tissue is reduced in morbidly obese patients. The primary objective of this exploratory pilot study is therefore to investigate target site (subcutaneous adipose tissue) penetration of cefazolin in morbidly obese patients and non-obese patients. The investigators aim to examine whether and how cefazolin plasma concentrations are predictive of subcutaneous (target) cefazolin concentrations. Possible factors of influence on the distribution of cefazolin (tissue perfusion, body weight, distribution of adipose tissue, other) will be identified.


Eligibility criteria: Inclusion Criteria:

* Body Mass Index \> 40 kg/m2
* BMI between 20-25
* undergoing laparoscopic gastric banding, or bypass surgery or sleeve gastrectomy (See population description for surgery type of the non-obese group)
* 21-60 years old
* American Society of Anaesthesiologists (ASA) physical status II to III

Exclusion Criteria:

* pregnancy
* breastfeeding
* known allergy for cefazolin/nadroparin
* known ejection fraction of \< 35%
* renal insufficiency

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nieuwegein
country: Netherlands
facility: St Antonius Hospital
state: Utrecht
city: Nieuwegein
country: Netherlands
facility: St Antonius Hospital
city: Nieuwegein
country: Netherlands
facility: St. antonius hospital
Study officials:
References:
citation: Diepstraten J, Janssen EJ, Hackeng CM, van Dongen EP, Wiezer RJ, van Ramshorst B, Knibbe CA. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol. 2015 Jan;71(1):25-34. doi: 10.1007/s00228-014-1760-4. Epub 2014 Oct 12.
citation: Brill MJ, Houwink AP, Schmidt S, Van Dongen EP, Hazebroek EJ, van Ramshorst B, Deneer VH, Mouton JW, Knibbe CA. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2014 Mar;69(3):715-23. doi: 10.1093/jac/dkt444. Epub 2013 Nov 8.
Clinical trial NCT00692952: Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial
Official title: Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Healthy
Keywords: contraceptive efficacy
Lead sponsor: Shanghai Institute of Planned Parenthood Research
Sponsor class: OTHER_GOV
Collaborators: name: Shanghai Municipal Commission of Health and Family Planning
name: Fudan University
name: International Peace Maternity and Child Health Hospital
name: Shanghai No. 1 Maternity and Child Care Center
name: Chang Jiang Bio-pharmaceutical Co., Ltd.
First posted: 2008-06-06
Enrollment: 240
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A multicentric clinical trial in three Chinese Maternal and Child Hospitals was conducted to evaluate the efficacy, safety and acceptability of newly-developed vaginal contraceptive gel, the optimized benzalkonium chloride (BZK) gel containing 18mg BZK, with comparison to a currently marketed (in China)contraceptive gel LELEMI® containing 50mg Nonoxynol-9 (N-9).

Detailed description: A phase II, multicentric,randomized, controlled clinical trial.

Eligibility criteria: Inclusion Criteria:

* at risk for pregnancy and desiring contraception
* having regular menstrual cycle (21-35 days)
* at low risk for HIV or other sexually transmitted infection
* sexually active
* use the test products as their primary method of contraception
* keep a diary of coital activity, product use, and adverse events

Exclusion Criteria:

* diagnosis of any vaginal infection or any symptom of STDs at baseline
* known allergy or hypersensitivity to N-9 or BZK
* menopause for more than one month
* breastfeeding
* vaginal bleeding with unknown reasons
* genitourinary system anomaly
* hysteroptosis II or severe cystocele
* moderate to severe erosion of cervix
* malignant reproductive system tumors

Primary outcomes:
measure: contraceptive efficacy
timeFrame: March 2004 - November 2005
Secondary outcomes:
measure: acceptability
timeFrame: March 2004 - November 2005
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Gynecology and Obstetrics Hospital of Fudan University
city: Shanghai
country: China
facility: International Peace Maternity and Child Care Center
city: Shanghai
country: China
facility: Shanghai No. 1 Maternity and Child Care Center
Study officials:
affiliation: Shanghai Municipal Commission of Health and Family Planning
name: Jinxun XU, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00167752: Psychiatric Problems in Chronic Skin Diseases
Official title: Quality of Life, Emotional and Sleep Problems in Chronic Skin Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psoriasis
Acne
Vitiligo
Atopic Dermatitis
Pruritic Dermatitis
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2005-09-14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to investigate the prevalence of depression, anxiety, and sleep problems in patients with chronic skin diseases in dermatology clinics at the University of Wisconsin Hospital and Clinics.


Eligibility criteria: Inclusion Criteria:

* Subjects suffering from a chronic skin condition that has lasted over six months

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Wisconsin, Madison
name: Ladan Mostaghimi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06086652: Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin
Official title: Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Metastasis of Unknown Origin
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-10-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Age \> 18 years Patients with metastatic tumor. Primary site was not detected with other radiological examinations Both male and female.

Brief summary: In most cases of malignancies, the site of origin of the cancer is clear at presentation or identified soon after. However, Metastatic cancer of unknown primary site (MUO) accounts for 3-5% of all malignant neoplasms, and it is defined as metastatic cancer from an unknown primary site, for which no original site can be detected even after performing all possible tests. Most common metastatic sites include the liver, lymph nodes, lungs, and bones.

18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) allows whole-body tumor detection and has proven to be useful in patients with metastasis of unknown primary tumor.


Eligibility criteria: Inclusion Criteria:

Age \> 18 years Patients with metastatic tumor. Primary site was not detected with other radiological examinations Both male and female.

Exclusion Criteria:

Patients with known primary tumor Pregnancy. Age \< 18 years.

Primary outcomes:
measure: primary tumor for metastasis of unknown origin
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university Hospital
Study officials:
References:
citation: van der Strate I, Kazemzadeh F, Nagtegaal ID, Robbrecht D, van de Wouw A, Padilla CS, Duijts S, Esteller M, Greco FA, Pavlidis N, Qaseem A, Snaebjornsson P, van Zanten SV, Loef C. International consensus on the initial diagnostic workup of cancer of unknown primary. Crit Rev Oncol Hematol. 2023 Jan;181:103868. doi: 10.1016/j.critrevonc.2022.103868. Epub 2022 Nov 23.
citation: Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009 Mar;19(3):731-44. doi: 10.1007/s00330-008-1194-4. Epub 2008 Oct 17.